Alterity director granted 2M share options

ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd , received a grant of unlisted options on June 15, 2026.

Rhea-AI Filing Summary

ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>, received a grant of unlisted options on June 15, 2026. The award covers 2,000,000 options, each exercisable into one ordinary share at an exercise price of 1.0000 per share, expiring on June 15, 2031. This is a compensation-related acquisition of derivative securities, not an open-market share purchase or sale, and leaves 2,000,000 options held indirectly following the transaction.

Insider Trade Summary

Grant/Award: 2,000,000 shares

Grant/Award 1 txn

Insider Babarczy Julian Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Unlisted option exp 15 Jun 2031	2,000,000	$0.00	$0.00

Holdings After Transaction: Unlisted option exp 15 Jun 2031 — 2,000,000 contracts (Indirect, Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>)

Key Figures

Options granted: 2,000,000 options Exercise price: 1.0000 per share Expiration date: June 15, 2031 +2 more

5 metrics

Options granted 2,000,000 options Grant of unlisted options on June 15, 2026

Exercise price 1.0000 per share Exercise price for each option

Expiration date June 15, 2031 Option term end date

Underlying shares 2,000,000 ordinary shares Shares issuable upon option exercise

Options after transaction 2,000,000 options Total derivative holdings following grant

Key Terms

Unlisted option, exercise price, expiration date, indirect ownership, +1 more

5 terms

Unlisted option financial

"Unlisted option exp 15 Jun 2031"

exercise price financial

"conversion_or_exercise_price: "1.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2031-06-15T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

indirect ownership financial

"ownership_type: "indirect", ownership_code: "I""

derivative securities financial

"transaction_type: "derivative""

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alterity Therapeutics (ATHE) disclose in this Form 4 filing?

Alterity Therapeutics reported that director Julian Michael Babarczy received 2,000,000 unlisted options as a compensation-related grant. These options are exercisable into ordinary shares and were awarded through an associated investment entity rather than via open-market share purchases or sales.

How many options were granted to the Alterity Therapeutics (ATHE) director?

The director was granted 2,000,000 unlisted options linked to Alterity Therapeutics ordinary shares. Each option represents the right to acquire one share, increasing his indirect derivative position to 2,000,000 options following this award, according to the reported post-transaction holdings.

What is the exercise price and term of the new ATHE options grant?

The newly granted options have an exercise price of 1.0000 per share and expire on June 15, 2031. This gives the holder a multi‑year window to decide whether to convert the options into Alterity Therapeutics ordinary shares at that fixed price.

Is the Alterity Therapeutics (ATHE) Form 4 transaction an open-market trade?

No, the Form 4 shows a grant or award acquisition of derivative securities, not an open-market stock trade. The 2,000,000 unlisted options were awarded as compensation and are held indirectly through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>.

How are the ATHE options held by director Julian Babarczy structured?

The 2,000,000 unlisted options are reported as indirectly owned through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>. This structure means the options are held via an associated investment account rather than directly in the director’s personal name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 07:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Babarczy Julian Michael

(Last) (First) (Middle)

LEVEL 15

500 COLLINS STREET

(Street)

MELBOURNE VICTORIA 3000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALTERITY THERAPEUTICS LTD [ ATHE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol
[ATH.ASX]

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Unlisted option exp 15 Jun 2031	$1	06/15/2026	06/15/2026	A		2,000,000		06/15/2026	06/15/2031	Ordinary shares	2,000,000	$0	2,000,000	I	Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>

Explanation of Responses:

	Julian Michael Babarczy	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)